Changeflow GovPing Healthcare & Life Sciences US20260109752A1: Extracellular Vesicle Platform...
Routine Notice Added Final

US20260109752A1: Extracellular Vesicle Platforms for Therapeutic Delivery

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO patent application US20260109752A1 covers platforms for generating extracellular vesicles, compositions of extracellular vesicles, and methods of using extracellular vesicles for therapeutics delivery. The application was filed on October 2, 2025 by inventors Milad Riazifar, Charles Cameron Taylor, and Todd Schurr (application No. 19348356). This is a publication of a patent application, not a granted patent.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 226 changes logged to date.

What changed

USPTO patent application US20260109752A1 discloses platforms for generating extracellular vesicles, compositions of extracellular vesicles, and methods for using extracellular vesicles in therapeutics delivery. The application lists CPC classifications including C07K 14/70521, A61K 9/5068, and A61P 29/00, indicating therapeutic applications. Inventors are Milad Riazifar, Charles Cameron Taylor, and Todd Schurr.

For pharmaceutical and biotechnology companies, this patent application represents potential prior art for freedom-to-operate analyses in the extracellular vesicle drug delivery space. Companies developing similar therapeutic delivery platforms should review the claims when the application proceeds to grant to assess potential infringement risks.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PLATFORMS, COMPOSITIONS, AND METHODS FOR THERAPEUTIC DELIVERY

Application US20260109752A1 Kind: A1 Apr 23, 2026

Inventors

Milad RIAZIFAR, Charles Cameron TAYLOR, Todd SCHURR

Abstract

Descried herein are platforms for generating extracellular vesicles. Described herein are compositions of extracellular vesicles. Also described herein are methods of using the extracellular vesicles for therapeutics delivery.

CPC Classifications

C07K 14/70521 A61K 9/5068 A61K 47/42 A61P 29/00 C07K 14/70503 C07K 14/70532 C07K 14/70596 A61K 38/00 C07K 2319/03

Filing Date

2025-10-02

Application No.

19348356

View original document →

Named provisions

Abstract Inventors CPC Classifications Filing Date Application No.

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Therapeutic delivery platforms Drug development Extracellular vesicle compositions
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!